Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Congress keeps SCHIP clean

  • News

Executive Summary

The House passed reauthorization for the State Children's Health Insurance Program Jan. 14, clearing the bill without any amendments that would affect the pharmaceutical industry. As a bill with strong support, it could have served as a vehicle for tweaking other government health care programs, such as striking the ban on government interference in drug price negotiations for Medicare Part D, but Congress seems content to wait for the broader health care reform debate to take shape

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Idorsia’s Novel Hypertension Pill Among Eight New Drugs To Win EMA Nod

AI Used In Drug R&D Likely Exempt From Tough EU AI Rules, Says EFPIA

EU Parliament OKs New Rules On Use Of Patient Data In Research

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

See All
UsernamePublicRestriction

Register

PS050554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By